Trehalose upregulates progranulin expression in human and mouse models of GRN haploinsufficiency: A novel therapeutic lead to treat frontotemporal dementia

Molecular Neurodegeneration

Volumn 11, Issue 1, 2016, Pages

  Holler, Christopher J ^a   Taylor, Georgia ^a   McEachin, Zachary T ^a,b   Deng, Qiudong ^a   Watkins, William J ^a   Hudson, Kathryn ^a   Easley, Charles A ^a   Hu, William T ^a   Hales, Chadwick M ^a   Rossoll, Wilfried ^a,b   Bassell, Gary J ^a,b   Kukar, Thomas ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Alzheimer's disease; Autophagy; Frontotemporal dementia; Frontotemporal lobar degeneration; Lysosome; Lysosome storage disease; Neurodegeneration; Neuronal ceroid lipofuscinosis; Parkinson's disease; Progranulin; TDP 43; TFEB; Trehalose; Ubiquitin

Indexed keywords

MESSENGER RNA; PROGRANULIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EB; TREHALOSE; UNCLASSIFIED DRUG; GRN PROTEIN, HUMAN; GRN PROTEIN, MOUSE; NEUROPROTECTIVE AGENT; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; BRAIN TISSUE; CONTROLLED STUDY; CYTOLYSIS; DRUG ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; GRN GENE; HAPLOINSUFFICIENCY; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOCYTOCHEMISTRY; LYSOSOME; MALE; MOUSE; NERVE CELL; NERVE CELL DIFFERENTIATION; NEUROPROTECTION; NONHUMAN; PLURIPOTENT STEM CELL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; PRECLINICAL STUDY;

ANIMALS; AUTOPHAGY; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FRONTOTEMPORAL DEMENTIA; GENE EXPRESSION; HAPLOINSUFFICIENCY; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROPROTECTIVE AGENTS; REAL-TIME POLYMERASE CHAIN REACTION; TREHALOSE; UP-REGULATION;

EID: 84975894236     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/s13024-016-0114-3     Document Type: Article

References (77)

1. Toh H, Chitramuthu BP, Bennett HP, Bateman A. Structure, function, and mechanism of progranulin; the brain and beyond. J Mol Neurosci. 2011;45(3):538-48. doi: 10.1007/s12031-011-9569-4.
2. Gass J, Lee WC, Cook C, Finch N, Stetler C, Jansen-West K, et al. Progranulin regulates neuronal outgrowth independent of sortilin. Mol Neurodegeneration. 2012;7:33. doi: 10.1186/1750-1326-7-33.
3. Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature. 2006;442(7105):920-4. doi: 10.1038/nature05017.
4. Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442(7105):916-9. doi: 10.1038/nature05016.
5. Gass J, Cannon A, Mackenzie IR, Boeve B, Baker M, Adamson J, et al. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet. 2006;15(20):2988-3001. doi: 10.1093/hmg/ddl241.
6. Perry DC, Lehmann M, Yokoyama JS, Karydas A, Lee JJ, Coppola G, et al. Progranulin mutations as risk factors for Alzheimer disease. JAMA Neurol. 2013;70(6):774-8. doi: 10.1001/2013.jamaneurol.393.
7. Sheng J, Su L, Xu Z, Chen G. Progranulin polymorphism rs5848 is associated with increased risk of Alzheimer's disease. Gene. 2014;542(2):141-5. doi: 10.1016/j.gene.2014.03.041.
8. Chen Y, Li S, Su L, Sheng J, Lv W, Chen G, et al. Association of progranulin polymorphism rs5848 with neurodegenerative diseases: a meta-analysis. J Neurol. 2015;262(4):814-22. doi: 10.1007/s00415-014-7630-2.
9. Petkau TL, Leavitt BR. Progranulin in neurodegenerative disease. Trends Neurosci. 2014;37(7):388-98. doi: 10.1016/j.tins.2014.04.003.
10. Gotzl JK, Mori K, Damme M, Fellerer K, Tahirovic S, Kleinberger G, et al. Common pathobiochemical hallmarks of progranulin-associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis. Acta Neuropathol. 2014;127(6):845-60. doi: 10.1007/s00401-014-1262-6.
11. Smith KR, Damiano J, Franceschetti S, Carpenter S, Canafoglia L, Morbin M, et al. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am J Hum Genet. 2012;90(6):1102-7. doi: 10.1016/j.ajhg.2012.04.021.
12. Roczniak-Ferguson A, Petit CS, Froehlich F, Qian S, Ky J, Angarola B, et al. The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. Sci Signal. 2012;5(228):ra42. doi: 10.1126/scisignal.2002790.
13. Cenik B, Sephton CF, Dewey CM, Xian X, Wei S, Yu K, et al. Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia. J Biol Chem. 2011;286(18):16101-8. doi: 10.1074/jbc.M110.193433.
14. Yin F, Banerjee R, Thomas B, Zhou P, Qian L, Jia T, et al. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med. 2010;207(1):117-28. doi: 10.1084/jem.20091568.
15. Hu F, Padukkavidana T, Vaegter CB, Brady OA, Zheng Y, Mackenzie IR, et al. Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron. 2010;68(4):654-67. doi: 10.1016/j.neuron.2010.09.034.
16. Gowrishankar S, Yuan P, Wu Y, Schrag M, Paradise S, Grutzendler J, et al. Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer's disease amyloid plaques. Proc Natl Acad Sci U S A. 2015;112(28):E3699-708. doi: 10.1073/pnas.1510329112.
17. Ahmed Z, Sheng H, Xu YF, Lin WL, Innes AE, Gass J, et al. Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am J Pathol. 2010;177(1):311-24. doi: 10.2353/ajpath.2010.090915.
18. Tanaka Y, Chambers JK, Matsuwaki T, Yamanouchi K, Nishihara M. Possible involvement of lysosomal dysfunction in pathological changes of the brain in aged progranulin-deficient mice. Acta neuropathol Commun. 2014;2:78. doi: 10.1186/s40478-014-0078-x.
19. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem. 2009;284(12):8023-32. doi: 10.1074/jbc.M900301200.
20. Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem. 2007;282(8):5641-52. doi: 10.1074/jbc.M609532200.
21. Kim YC, Guan KL. mTOR: a pharmacologic target for autophagy regulation. J Clin Invest. 2015;125(1):25-32. doi: 10.1172/JCI73939.
22. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012;8(4):445-544.
23. Zhang X, Chen S, Song L, Tang Y, Shen Y, Jia L, et al. MTOR-independent, autophagic enhancer trehalose prolongs motor neuron survival and ameliorates the autophagic flux defect in a mouse model of amyotrophic lateral sclerosis. Autophagy. 2014;10(4):588-602. doi: 10.4161/auto.27710.
24. Castillo K, Nassif M, Valenzuela V, Rojas F, Matus S, Mercado G, et al. Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons. Autophagy. 2013;9(9):1308-20. doi: 10.4161/auto.25188.
25. Capell A, Liebscher S, Fellerer K, Brouwers N, Willem M, Lammich S, et al. Rescue of progranulin deficiency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase. J Neurosci. 2011;31(5):1885-94. doi: 10.1523/JNEUROSCI.5757-10.2011.
26. Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, Gennarino VA, et al. A gene network regulating lysosomal biogenesis and function. Science. 2009;325(5939):473-7. doi: 10.1126/science.1174447.
27. Settembre C, Di Malta C, Polito VA, Garcia Arencibia M, Vetrini F, Erdin S, et al. TFEB links autophagy to lysosomal biogenesis. Science. 2011;332(6036):1429-33. doi: 10.1126/science.1204592.
28. Belcastro V, Siciliano V, Gregoretti F, Mithbaokar P, Dharmalingam G, Berlingieri S, et al. Transcriptional gene network inference from a massive dataset elucidates transcriptome organization and gene function. Nucleic Acids Res. 2011;39(20):8677-88. doi: 10.1093/nar/gkr593.
29. Tanaka Y, Matsuwaki T, Yamanouchi K, Nishihara M. Increased lysosomal biogenesis in activated microglia and exacerbated neuronal damage after traumatic brain injury in progranulin-deficient mice. Neuroscience. 2013;250:8-19. doi: 10.1016/j.neuroscience.2013.06.049.
30. Dehay B, Bove J, Rodriguez-Muela N, Perier C, Recasens A, Boya P, et al. Pathogenic lysosomal depletion in Parkinson's disease. J Neurosci. 2010;30(37):12535-44. doi: 10.1523/JNEUROSCI.1920-10.2010.
31. Uchida K, Unuma K, Funakoshi T, Aki T, Uemura K. Activation of Master Autophagy Regulator TFEB During Systemic LPS Administration in the Cornea. Journal toxicol Pathol. 2014;27(2):153-8. doi: 10.1293/tox.2014-0004.
32. Settembre C, Zoncu R, Medina DL, Vetrini F, Erdin S, Erdin S, et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J. 2012;31(5):1095-108. doi: 10.1038/emboj.2012.32.
33. Martina JA, Chen Y, Gucek M, Puertollano R. MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB. Autophagy. 2012;8(6):903-14. doi: 10.4161/auto.19653.
34. Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology. 2008;71(16):1235-9. doi: 10.1212/01.wnl.0000325058.10218.fc.
35. Finch N, Baker M, Crook R, Swanson K, Kuntz K, Surtees R, et al. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain. 2009;132(Pt 3):583-91. doi: 10.1093/brain/awn352.
36. Sleegers K, Brouwers N, Van Damme P, Engelborghs S, Gijselinck I, van der Zee J, et al. Serum biomarker for progranulin-associated frontotemporal lobar degeneration. Ann Neurol. 2009;65(5):603-9. doi: 10.1002/ana.21621.
37. Benussi L, Ciani M, Tonoli E, Morbin M, Palamara L, Albani D, et al. Loss of exosomes in progranulin-associated frontotemporal dementia. Neurobiol Aging. 2016;40:41-9. doi: 10.1016/j.neurobiolaging.2016.01.001.
38. Schaeffer V, Lavenir I, Ozcelik S, Tolnay M, Winkler DT, Goedert M. Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain. 2012;135(Pt 7):2169-77. doi: 10.1093/brain/aws143.
39. Tanaka M, Machida Y, Niu S, Ikeda T, Jana NR, Doi H, et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med. 2004;10(2):148-54. doi: 10.1038/nm985.
40. Davies JE, Sarkar S, Rubinsztein DC. Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. Hum Mol Genet. 2006;15(1):23-31. doi: 10.1093/hmg/ddi422.
41. Liu M, Zhang M, Ye H, Lin S, Yang Y, Wang L, et al. Multiple toxicity studies of trehalose in mice by intragastric administration. Food Chem. 2013;136(2):485-90. doi: 10.1016/j.foodchem.2012.09.031.
42. Richards AB, Krakowka S, Dexter LB, Schmid H, Wolterbeek AP, Waalkens-Berendsen DH, et al. Trehalose: a review of properties, history of use and human tolerance, and results of multiple safety studies. Food Chem Toxicol. 2002;40(7):871-98.
43. Nicholson AM, Finch NA, Thomas CS, Wojtas A, Rutherford NJ, Mielke MM, et al. Progranulin protein levels are differently regulated in plasma and CSF. Neurology. 2014;82(21):1871-8. doi: 10.1212/WNL.0000000000000445.
44. Morenas-Rodriguez E, Cervera-Carles L, Vilaplana E, Alcolea D, Carmona-Iragui M, Dols-Icardo O, et al. Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias. J Alzheimers Dis. 2015;50(2):539-46. doi: 10.3233/JAD-150746.
45. Raitano S, Ordovas L, De Muynck L, Guo W, Espuny-Camacho I, Geraerts M, et al. Restoration of progranulin expression rescues cortical neuron generation in an induced pluripotent stem cell model of frontotemporal dementia. Stem Cell Rep. 2015;4(1):16-24. doi: 10.1016/j.stemcr.2014.12.001.
46. Xu J, Xilouri M, Bruban J, Shioi J, Shao Z, Papazoglou I, et al. Extracellular progranulin protects cortical neurons from toxic insults by activating survival signaling. Neurobiology of aging. 2011;32(12):2326 e5-16. doi: 10.1016/j.neurobiolaging.2011.06.017.
47. Van Kampen JM, Baranowski D, Kay DG. Progranulin gene delivery protects dopaminergic neurons in a mouse model of Parkinson's disease. PLoS One. 2014;9(5):e97032. doi: 10.1371/journal.pone.0097032.
48. Minami SS, Min SW, Krabbe G, Wang C, Zhou Y, Asgarov R, et al. Progranulin protects against amyloid beta deposition and toxicity in Alzheimer's disease mouse models. Nat Med. 2014;20(10):1157-64. doi: 10.1038/nm.3672.
49. Li M, Khambu B, Zhang H, Kang JH, Chen X, Chen D, et al. Suppression of lysosome function induces autophagy via a feedback down-regulation of MTOR complex 1 (MTORC1) activity. J Biol Chem. 2013;288(50):35769-80. doi: 10.1074/jbc.M113.511212.
50. Kubisch R, Fröhlich T, Arnold GJ, Schreiner L, von Schwarzenberg K, Roidl A, et al. V-ATPase inhibition by archazolid leads to lysosomal dysfunction resulting in impaired cathepsin B activation in vivo. Int J Cancer. 2014;134(10):2478-88. doi: 10.1002/ijc.28562.
51. Chiao MT, Cheng WY, Yang YC, Shen CC, Ko JL. Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells. Autophagy. 2013;9(10):1509-26. doi: 10.4161/auto.25664.
52. Zhou X, Sun L, Bastos de Oliveira F, Qi X, Brown WJ, Smolka MB, et al. Prosaposin facilitates sortilin-independent lysosomal trafficking of progranulin. J Cell Biol. 2015;210(6):991-1002. doi: 10.1083/jcb.201502029.
53. Almeida S, Zhang Z, Coppola G, Mao W, Futai K, Karydas A, et al. Induced pluripotent stem cell models of progranulin-deficient frontotemporal dementia uncover specific reversible neuronal defects. Cell Rep. 2012;2(4):789-98. doi: 10.1016/j.celrep.2012.09.007.
54. Hu SY, Tai CC, Li YH, Wu JL. Progranulin compensates for blocked IGF-1 signaling to promote myotube hypertrophy in C2C12 myoblasts via the PI3K/Akt/mTOR pathway. FEBS Lett. 2012;586(19):3485-92. doi: 10.1016/j.febslet.2012.07.077.
55. Lopez E, Berna-Erro A, Bermejo N, Brull JM, Martinez R, Garcia Pino G, et al. Long-term mTOR inhibitors administration evokes altered calcium homeostasis and platelet dysfunction in kidney transplant patients. J Cell Mol Med. 2013;17(5):636-47. doi: 10.1111/jcmm.12044.
56. Perluigi M, Di Domenico F, Butterfield DA. mTOR signaling in aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy. Neurobiol Dis. 2015. doi: 10.1016/j.nbd.2015.03.014.
57. Kruger U, Wang Y, Kumar S, Mandelkow EM. Autophagic degradation of tau in primary neurons and its enhancement by trehalose. Neurobiol Aging. 2012;33(10):2291-305. doi: 10.1016/j.neurobiolaging.2011.11.009.
58. Castillo K, Valenzuela V, Matus S, Nassif M, Onate M, Fuentealba Y, et al. Measurement of autophagy flux in the nervous system in vivo. Cell Death Dis. 2013;4:e917. doi: 10.1038/cddis.2013.421.
59. Perucho J, Casarejos MJ, Gomez A, Solano RM, de Yebenes JG, Mena MA. Trehalose protects from aggravation of amyloid pathology induced by isoflurane anesthesia in APP(swe) mutant mice. Curr Alzheimer Res. 2012;9(3):334-43.
60. Rodriguez-Navarro JA, Rodriguez L, Casarejos MJ, Solano RM, Gomez A, Perucho J, et al. Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation. Neurobiol Dis. 2010;39(3):423-38. doi: 10.1016/j.nbd.2010.05.014.
61. Lei Z, Brizzee C, Johnson GV. BAG3 facilitates the clearance of endogenous tau in primary neurons. Neurobiol Aging. 2015;36(1):241-8. doi: 10.1016/j.neurobiolaging.2014.08.012.
62. Fernandez-Estevez MA, Casarejos MJ, Lopez Sendon J, Garcia Caldentey J, Ruiz C, Gomez A, et al. Trehalose reverses cell malfunction in fibroblasts from normal and Huntington's disease patients caused by proteosome inhibition. PLoS One. 2014;9(2):e90202. doi: 10.1371/journal.pone.0090202.
63. Yang CR, Yu RK. Intracerebral transplantation of neural stem cells combined with trehalose ingestion alleviates pathology in a mouse model of Huntington's disease. J Neurosci Res. 2009;87(1):26-33. doi: 10.1002/jnr.21817.
64. Li Y, Guo Y, Wang X, Yu X, Duan W, Hong K, et al. Trehalose decreases mutant SOD1 expression and alleviates motor deficiency in early but not end-stage amyotrophic lateral sclerosis in a SOD1-G93A mouse model. Neuroscience. 2015;298:12-25. doi: 10.1016/j.neuroscience.2015.03.061.
65. Casarejos MJ, Solano RM, Gomez A, Perucho J, de Yebenes JG, Mena MA. The accumulation of neurotoxic proteins, induced by proteasome inhibition, is reverted by trehalose, an enhancer of autophagy, in human neuroblastoma cells. Neurochem Int. 2011;58(4):512-20. doi: 10.1016/j.neuint.2011.01.008.
66. Lan DM, Liu FT, Zhao J, Chen Y, Wu JJ, Ding ZT, et al. Effect of trehalose on PC12 cells overexpressing wild-type or A53T mutant alpha-synuclein. Neurochem Res. 2012;37(9):2025-32. doi: 10.1007/s11064-012-0823-0.
67. He Q, Koprich JB, Wang Y, Yu WB, Xiao BG, Brotchie JM, et al. Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV alpha-Synuclein Rat Model of Parkinson's Disease. Mol Neurobiol. 2015. doi: 10.1007/s12035-015-9173-7.
68. Aguib Y, Heiseke A, Gilch S, Riemer C, Baier M, Schatzl HM, et al. Autophagy induction by trehalose counteracts cellular prion infection. Autophagy. 2009;5(3):361-9.
69. Beranger F, Crozet C, Goldsborough A, Lehmann S. Trehalose impairs aggregation of PrPSc molecules and protects prion-infected cells against oxidative damage. Biochem Biophys Res Commun. 2008;374(1):44-8. doi: 10.1016/j.bbrc.2008.06.094.
70. Wang X, Fan H, Ying Z, Li B, Wang H, Wang G. Degradation of TDP-43 and its pathogenic form by autophagy and the ubiquitin-proteasome system. Neurosci Lett. 2010;469(1):112-6. doi: 10.1016/j.neulet.2009.11.055.
71. Honda Y, Tanaka M, Honda S. Trehalose extends longevity in the nematode Caenorhabditis elegans. Aging Cell. 2010;9(4):558-69. doi: 10.1111/j.1474-9726.2010.00582.x.
72. Minutoli L, Altavilla D, Bitto A, Polito F, Bellocco E, Lagana G, et al. The disaccharide trehalose inhibits proinflammatory phenotype activation in macrophages and prevents mortality in experimental septic shock. Shock. 2007;27(1):91-6. doi: 10.1097/01.shk.0000235092.76292.bc.
73. LaRocca TJ, Henson GD, Thorburn A, Sindler AL, Pierce GL, Seals DR. Translational evidence that impaired autophagy contributes to arterial ageing. J Physiol. 2012;590(Pt 14):3305-16. doi: 10.1113/jphysiol.2012.229690.
74. Echigo R, Shimohata N, Karatsu K, Yano F, Kayasuga-Kariya Y, Fujisawa A, et al. Trehalose treatment suppresses inflammation, oxidative stress, and vasospasm induced by experimental subarachnoid hemorrhage. J Transl Med. 2012;10:80. doi: 10.1186/1479-5876-10-80.
75. Filiano AJ, Martens LH, Young AH, Warmus BA, Zhou P, Diaz-Ramirez G, et al. Dissociation of frontotemporal dementia-related deficits and neuroinflammation in progranulin haploinsufficient mice. J Neurosci. 2013;33(12):5352-61. doi: 10.1523/JNEUROSCI.6103-11.2013.
76. Wada S, Ohba S, Someno T, Hatano M, Nomoto A. Structure and biological properties of lentztrehalose: a novel trehalose analog. J Antibiot. 2014;67(4):319-22. doi: 10.1038/ja.2013.143.
77. Abazari A, Meimetis LG, Budin G, Bale SS, Weissleder R, Toner M. Engineered Trehalose Permeable to Mammalian Cells. PLoS One. 2015;10(6):e0130323. doi: 10.1371/journal.pone.0130323.